Advertisement

Topics

Proximagen Neuroscience plc Company Profile

11:04 EDT 25th September 2018 | BioPortfolio

Proximagen Neuroscience plc is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Proximagen is building a compound pipeline to address the significant unmet medical needs of patients with neurodegenerative disease through its own discovery programme for novel, low risk therapeutic candidates, and through the identification and licensing of existing drugs for new indications.

Location

Hodgkin Building
Guy's Campus King's College London
London
London
SE1 1UL
United States of America

Contact

Phone: +44(0)207.848.6938
Fax: +44(0)207.848.6034
Email: info@proximagen.com


News Articles [370 Associated News Articles listed on BioPortfolio]

Proximagen grants UCB rights to seizure candidate

Proximagen, a subsidiary of Acova, granted UCB rights to USL261, or intranasal midazolam, in a deal that gave Proximagen an u -More- 

Belgium’s UCB buys Proximagen’s epilepsy drug

Belgian biopharmaceutical company UCB has acquired an anti-epilepsy medication, Midazolam nasal spray (USL261), from Proximagen for $150m. As well as...Read More... The post Belgium’s UCB buys Proxi...

Tim Sparey, Head of Business Development talks about Proximagen’s partnering strategy.

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tim Sparey, Head of Business Development at Proximagen

12th Annual Canadian Neuroscience Meeting

(Canadian Association for Neuroscience) The 12th annual Canadian Neuroscience Meeting will bring together over 700 neuroscientists from Canada and abroad to share the latest discoveries about the brai...

UCB Buys Rights to Proximagen Antiepilepsy Nasal Spray for Up to $370M

UCB said today it has acquired rights to Proximagen’s New Drug Application (NDA)-bound antiepilepsy candidate Midazolam Nasal Spray (USL261) for up to $370 million. Midazolam is being developed ...

UCB Buys Rights to Proximagen Anti-Epilepsy Nasal Spray for Up to $370M

UCB said today it has acquired rights to Proximagen’s NDA-bound anti-epilepsy candidate Midazolam Nasal Spray (USL261)1 for up to $370 million. Midazolam is being developed as a rescue treatment...

Portrait of a Neuroscience Powerhouse

At noon every Tuesday from September through June, scenes from a revolution in neuroscience are playing out at Cold Spring Harbor Laboratory. Week after week, over 100 scientists cram themselves into ...

Neuroscience In the Gallery

The Netherlands Institute for Neuroscience is seeking entries for a competition that celebrates visual art inspired by the brain -- Read more on ScientificAmerican.com

PubMed Articles [328 Associated PubMed Articles listed on BioPortfolio]

Reflections Over 50 Years of Pediatric Neuroscience Nursing.

Throughout the past 50 years, the role of the neuroscience nurse has become more specialized as we continue to keep pace with new innovations and improvement in care for our patients. This is evident ...

Visions for the Future of Neuroscience.

Neuroscience is a broad discipline that embraces technology at multiple scales to understand the brain and to develop potential therapies. Scientists share their perspectives on the evolution of neuro...

Adding new dimension to neuroscience.

Corrigendum to "Neuroprotective Effect of Sirt2-specific Inhibitor AK-7 Against Acute Cerebral Ischemia is P38 Activation-dependent in Mice" Neuroscience 374 (2018) 61-69.

Corrigendum to "Prevention of the Severity of Post-ischemic Inflammation and Brain Damage by Simultaneous Knockdown of Toll-like Receptors 2 and 4" Neuroscience 373 (2018) 82-91.

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Precision Psychiatry Continuity Clinic Project

This is a demonstration project focused on translating neuroscience insights into clinical practice. The researchers will evaluate how neuroscience assessments may be applied in the clinic...

Exercise and Pain Neuroscience Education for Patients With Neck Pain: Impact on Pain and Disability

This study will compare the effectiveness of pain neuroscience education and neck/shoulder traditional exercises versus pain neuroscience education and neck/shoulder suspension training ex...

Pain Neuroscience Education in Healthy Children

The primary objective of this study is to examine whether Pain Neuroscience Education for children is able to increase a child's knowledge on the neurophysiology of pain. In addition, thi...

Pain Neuroscience Education and Exercise

This study examined the effects of pain neuroscience education plus exercise when compared with exercise only in university students with chronic idiopathic neck pain.

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and ...

Companies [150 Associated Companies listed on BioPortfolio]

Proximagen Neuroscience plc

Proximagen Neuroscience plc is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. Prox...

Neurosciences Victoria Limited

Our MissionNSV is dedicated to the continued development of the world-class neuroscience biocluster in Melbourne, Australia through a program of strategic investment in the gap between academic discov...

Society for Neuroscience

The Society for Neuroscience is a nonprofit membership organization of basic scientists and physicians who study the brain and nervous system. Recognizing the field's tremendous potential, the Society...

Cambridge NeuroScience Incorporated

Cambridge NeuroScience Incorporated is a biopharmaceutical company engaged in the discovery and development of proprietary pharmaceuticals to prevent or treat severe disorders of, or injuries to, the ...

Neurosciences Victoria Ltd

NSV® was formed in 2001 to facilitate technology transfer and inward investment into the vibrant and expanding Melbourne neuroscience cluster.NSV provides a "one-stop-shop" for current and potential ...

More Information about "Proximagen Neuroscience plc" on BioPortfolio

We have published hundreds of Proximagen Neuroscience plc news stories on BioPortfolio along with dozens of Proximagen Neuroscience plc Clinical Trials and PubMed Articles about Proximagen Neuroscience plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Proximagen Neuroscience plc Companies in our database. You can also find out about relevant Proximagen Neuroscience plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record